Novel Cannabinoid Receptor 2 (CB2) Low Lipophilicity Agonists Produce Distinct cAMP and Arrestin Signalling Kinetics without Bias

Cannabinoid Receptor 2 (CB2) is a promising target for treating inflammatory diseases. We designed derivatives of 3-carbamoyl-2-pyridone and 1,8-naphthyridin-2(1H)-one-3-carboxamide CB2-selective agonists with reduced lipophilicity. The new compounds were measured for their affinity (radioligand bin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Raahul, Singh, Sameek, Whiting, Zak M., Molitor, Maximilian, Vernall, Andrea J., Grimsey, Natasha L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094510/
https://www.ncbi.nlm.nih.gov/pubmed/37047385
http://dx.doi.org/10.3390/ijms24076406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094510/
https://www.ncbi.nlm.nih.gov/pubmed/37047385
http://dx.doi.org/10.3390/ijms24076406

Ejemplares similares